Sone Capital Management LLC Makes New Investment in DexCom, Inc. $DXCM

Sone Capital Management LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 33,380 shares of the medical device company’s stock, valued at approximately $2,248,000.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after buying an additional 42,411 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in DexCom by 6.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after acquiring an additional 516,526 shares in the last quarter. Norges Bank purchased a new stake in DexCom in the fourth quarter valued at approximately $483,356,000. Invesco Ltd. raised its position in DexCom by 14.8% in the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of DexCom by 7.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after buying an additional 220,313 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $91.06 on Tuesday. The company has a market cap of $34.36 billion, a P/E ratio of 35.99, a PEG ratio of 1.56 and a beta of 1.41. The business has a 50 day moving average of $77.83 and a two-hundred day moving average of $71.07. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.48 EPS. As a group, analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

Insiders Place Their Bets

In related news, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the transaction, the insider owned 328,970 shares in the company, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of DexCom stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 73,035 shares of company stock worth $5,446,673. Insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DXCM. Royal Bank Of Canada boosted their target price on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Weiss Ratings upgraded shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $90.00 price objective (up from $80.00) on shares of DexCom in a research report on Friday, July 31st. UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Benchmark upped their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.